| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?
|
Grob, Jean Jacques
|
|
|
19 |
12 |
p. e720-e725
|
artikel
|
| 2 |
Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study
|
Malagón, Talía
|
|
|
19 |
12 |
p. 1569-1578
|
artikel
|
| 3 |
Beyond resumption of the Japanese Government's recommendation of the HPV vaccine
|
Ueda, Yutaka
|
|
|
19 |
12 |
p. 1563-1564
|
artikel
|
| 4 |
Biomarkers in renal-cell carcinoma: building on clinical paradigms
|
Agarwal, Neeraj
|
|
|
19 |
12 |
p. 1560-1561
|
artikel
|
| 5 |
Cancer trends and burden in India
|
Kalita, Manoj
|
|
|
19 |
12 |
p. e661
|
artikel
|
| 6 |
Cancer trends and burden in India
|
Krishnatreya, Manigreeva
|
|
|
19 |
12 |
p. e660
|
artikel
|
| 7 |
Cancer trends and burden in India
|
Mathew, Aju
|
|
|
19 |
12 |
p. e662
|
artikel
|
| 8 |
Cancer trends and burden in India
|
K, Chandramohan
|
|
|
19 |
12 |
p. e663
|
artikel
|
| 9 |
Cancer trends and burden in India – Authors' response
|
Mathur, Prashant
|
|
|
19 |
12 |
p. e664
|
artikel
|
| 10 |
Carcinogenicity of some nitrobenzenes and other industrial chemicals
|
|
|
|
19 |
12 |
p. e681-e682
|
artikel
|
| 11 |
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
|
Salem, Joe-Elie
|
|
|
19 |
12 |
p. 1579-1589
|
artikel
|
| 12 |
Consensus on molecular imaging and theranostics in prostate cancer
|
Fanti, Stefano
|
|
|
19 |
12 |
p. e696-e708
|
artikel
|
| 13 |
Correction to Lancet Oncol 2017; 18: 52–62
|
|
|
|
19 |
12 |
p. e667
|
artikel
|
| 14 |
Correction to Lancet Oncol 2018; 19: 1516–29
|
|
|
|
19 |
12 |
p. e668
|
artikel
|
| 15 |
Correction to Lancet Oncol 2014; 15: 640–47
|
|
|
|
19 |
12 |
p. e667
|
artikel
|
| 16 |
Correction to Lancet Oncol 2018; 19: 1437–48
|
|
|
|
19 |
12 |
p. e668
|
artikel
|
| 17 |
Correction to Lancet Oncol 2018; 19: 1480–92
|
|
|
|
19 |
12 |
p. e668
|
artikel
|
| 18 |
Correction to Lancet Oncol 2017; 18: 1360–72
|
|
|
|
19 |
12 |
p. e667
|
artikel
|
| 19 |
Correction to Lancet Oncol 2017; 18: 732–42
|
|
|
|
19 |
12 |
p. e667
|
artikel
|
| 20 |
Correction to Lancet Oncol 2017; 18: e638
|
|
|
|
19 |
12 |
p. e667-e668
|
artikel
|
| 21 |
Defining priority medical devices for cancer management: a WHO initiative
|
Velazquez Berumen, Adriana
|
|
|
19 |
12 |
p. e709-e719
|
artikel
|
| 22 |
E-cigarettes—new product, old tricks
|
The Lancet Oncology,
|
|
|
19 |
12 |
p. 1543
|
artikel
|
| 23 |
Elotuzumab in multiple myeloma
|
Burki, Talha Khan
|
|
|
19 |
12 |
p. e675
|
artikel
|
| 24 |
European Society of Medical Oncology 2018 Congress
|
Sklan, Alex
|
|
|
19 |
12 |
p. e678
|
artikel
|
| 25 |
Evidence-based screening protocols for cervical cancer?
|
Rossi, Paolo Giorgi
|
|
|
19 |
12 |
p. 1544-1545
|
artikel
|
| 26 |
Evolution of monoclonal antibodies in multiple myeloma
|
Musto, Pellegrino
|
|
|
19 |
12 |
p. 1554-1555
|
artikel
|
| 27 |
Fine-tuning chemotherapy in the era of dual HER2 targeting
|
Loi, Sherene
|
|
|
19 |
12 |
p. 1551-1554
|
artikel
|
| 28 |
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study
|
Voss, Martin H
|
|
|
19 |
12 |
p. 1688-1698
|
artikel
|
| 29 |
Immunotherapy toxicity predicted by circulating cytokines
|
Gourd, Elizabeth
|
|
|
19 |
12 |
p. e676
|
artikel
|
| 30 |
Interleukin 2 plus anti-GD2 immunotherapy: helpful or harmful?
|
Matthay, Katherine K
|
|
|
19 |
12 |
p. 1549-1551
|
artikel
|
| 31 |
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
|
Ladenstein, Ruth
|
|
|
19 |
12 |
p. 1617-1629
|
artikel
|
| 32 |
Interrogating molecular data for medulloblastoma risk stratification
|
Ferretti, Elisabetta
|
|
|
19 |
12 |
p. 1548-1549
|
artikel
|
| 33 |
Long-term follow-up care needed for children surviving cancer: still a long way to go
|
Winther, Jeanette F
|
|
|
19 |
12 |
p. 1546-1548
|
artikel
|
| 34 |
Lorlatinib: a new-generation drug for ALK-positive NSCLC
|
Waqar, Saiama N
|
|
|
19 |
12 |
p. 1555-1557
|
artikel
|
| 35 |
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
|
Solomon, Benjamin J
|
|
|
19 |
12 |
p. 1654-1667
|
artikel
|
| 36 |
Lung squamous carcinoma involving the lip and cheek
|
Yan, Binjie
|
|
|
19 |
12 |
p. e726
|
artikel
|
| 37 |
Maintenance olaparib in advanced ovarian cancer
|
Burki, Talha Khan
|
|
|
19 |
12 |
p. e671
|
artikel
|
| 38 |
Mandatory bundled payment model for US cancer patients
|
Das, Manjulika
|
|
|
19 |
12 |
p. e677
|
artikel
|
| 39 |
Maternal use of hormonal contraception and risk of childhood leukaemia
|
Cao, Yubin
|
|
|
19 |
12 |
p. e657
|
artikel
|
| 40 |
Maternal use of hormonal contraception and risk of childhood leukaemia
|
Huang, Yongmei
|
|
|
19 |
12 |
p. e658
|
artikel
|
| 41 |
Maternal use of hormonal contraception and risk of childhood leukaemia – Authors' reply
|
Hargreave, Marie
|
|
|
19 |
12 |
p. e659
|
artikel
|
| 42 |
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
|
Platzbecker, Uwe
|
|
|
19 |
12 |
p. 1668-1679
|
artikel
|
| 43 |
Meta-analyses and RCTs in oncology—what is the right balance?
|
Gyawali, Bishal
|
|
|
19 |
12 |
p. 1565-1566
|
artikel
|
| 44 |
Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer
|
Miyamoto, David T
|
|
|
19 |
12 |
p. e683-e695
|
artikel
|
| 45 |
National cancer control plans
|
Nicholson, Brian D
|
|
|
19 |
12 |
p. e665
|
artikel
|
| 46 |
National cancer control plans
|
Garvey, Gail
|
|
|
19 |
12 |
p. e666
|
artikel
|
| 47 |
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
|
Vergote, Ignace
|
|
|
19 |
12 |
p. 1680-1687
|
artikel
|
| 48 |
Neoadjuvant chemotherapy versus upfront debulking surgery in advanced tubo-ovarian cancer
|
Fagotti, Anna
|
|
|
19 |
12 |
p. 1558-1560
|
artikel
|
| 49 |
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
|
van Ramshorst, Mette S
|
|
|
19 |
12 |
p. 1630-1640
|
artikel
|
| 50 |
Neoadjuvant pembrolizumab in bladder cancer
|
Gourd, Elizabeth
|
|
|
19 |
12 |
p. e669
|
artikel
|
| 51 |
Outcomes after minimally invasive surgery in cervical cancer
|
Burki, Talha Khan
|
|
|
19 |
12 |
p. e674
|
artikel
|
| 52 |
Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors
|
Varricchi, Gilda
|
|
|
19 |
12 |
p. 1545-1546
|
artikel
|
| 53 |
Pre-emptive azacitidine for relapse prevention in acute myeloid leukaemia
|
Ramos, Fernando
|
|
|
19 |
12 |
p. 1557-1558
|
artikel
|
| 54 |
Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
|
Goschzik, Tobias
|
|
|
19 |
12 |
p. 1602-1616
|
artikel
|
| 55 |
Promising new treatment for multiple myeloma
|
Gourd, Elizabeth
|
|
|
19 |
12 |
p. e673
|
artikel
|
| 56 |
Pseudoprogression: fact or wishful thinking in neuro-oncology?
|
Reardon, David A
|
|
|
19 |
12 |
p. 1561-1563
|
artikel
|
| 57 |
Surveillance imaging of Wilms' tumours
|
Stirrups, Robert
|
|
|
19 |
12 |
p. e670
|
artikel
|
| 58 |
Tailoring adjuvant treatment in patients with uterine cancer
|
Bogani, Giorgio
|
|
|
19 |
12 |
p. e655
|
artikel
|
| 59 |
Tailoring adjuvant treatment in patients with uterine cancer – Authors' reply
|
Frumovitz, Michael
|
|
|
19 |
12 |
p. e656
|
artikel
|
| 60 |
Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
|
Trudel, Suzanne
|
|
|
19 |
12 |
p. 1641-1653
|
artikel
|
| 61 |
Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort
|
Gibson, Todd M
|
|
|
19 |
12 |
p. 1590-1601
|
artikel
|
| 62 |
60th ASTRO Annual Meeting
|
Lai, Cheryl
|
|
|
19 |
12 |
p. e679-e680
|
artikel
|
| 63 |
Venetoclax with decitabine or azacitidine for AML
|
Das, Manjulika
|
|
|
19 |
12 |
p. e672
|
artikel
|
| 64 |
Yale Cancer Center Precision Medicine Tumor Board: one tumour, multiple targets
|
Stewart, Tyler
|
|
|
19 |
12 |
p. 1567-1568
|
artikel
|
Tijdschrift beschrijving